---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-078060"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T12:48:57.504910+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Traws Pharma Q2 net loss narrows to $0.9M; cash drops to $13.1M; Phase 2 COVID study planned

## Summary
- Net loss of $0.9M ($0.11/share) vs. $123.1M loss in Q2 2024 which included $117.5M acquisition charge.
- Revenue $2.7M (vs. $57K) from deferred revenue on mutual termination of an oncology license.
- Cash, cash equivalents and investments $13.1M as of June 30, down from $21.3M at Dec 31, 2024.
- Phase 2 ratutrelvir (COVID) study submitted to HREC in Australia; results expected by year-end 2025.
- Bird flu Phase 2 study deferred; BARDA stockpile discussions continue; Charles Parker named Interim CFO.

## SEC filing metadata
- accession: 0001104659-25-078060
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465925078060/0001104659-25-078060-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465925078060/tm2523498d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-078060
- JSON: https://secwatch.observer/filing/0001104659-25-078060.json
- Plain text: https://secwatch.observer/filing/0001104659-25-078060.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.